$90.14
Today
as of Jul 22, 16:47 ET
Last 30 days
Recent Press Releases & News
Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval
Celcuity gains FDA approval for closely watched breast cancer drug
Celcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer
Overview
52-week range
$11
$151
56% of range
Avg surprise (last 3)
+1.1%
Avg reaction (last 2)
+4.3%
100% positive
Latest IV / EM
75%
EM ±17.2% · $90 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 14, 2026 | Mar/2026 | $-0.97 | $-1.07 | +9.3% | -12.8% | +8.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.92 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-1.04 | $-0.90 | -15.6% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.86 | $-0.95 | +9.5% | — | +0.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.70 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.62 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.64 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.83 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.66 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 13, 2026 | Jun/2026 | OTHER | -$1.08 | -$1.04 | -3.9% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-51M | — | $-43M | $-44M | $-36M | — | $-30M | $-24M |
| Net income | $-53M | — | $-44M | $-45M | $-37M | — | $-30M | $-24M |
| EPS (diluted) | $-0.97 | — | $-0.92 | $-1.04 | $-0.86 | — | $-0.70 | $-0.62 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $145M | $166M | $74M | $46M | $16M | $23M | $13M | $30M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $409M | $466M | $475M | $183M | $218M | $245M | $272M | $292M |
| Total assets | $410M | $467M | $476M | $184M | $218M | $245M | $273M | $293M |
| Long-term debt | $138M | — | $137M | $106M | $105M | — | $105M | $105M |
| Total liabilities | $357M | $366M | $359M | $139M | $131M | $130M | $123M | $116M |
| Total equity | $54M | $101M | $117M | $44M | $87M | $116M | $150M | $177M |